English
SpanishTrusted Resources: Community Center
Online groups, photo galleries and blogs
An Interview With Muscular Dystrophy Association President Donald S. Wood
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Donald S. Wood, PhD, President and CEO of the Muscular Dystrophy Association (MDA). Their conversation focuses on the latest therapies for Duchenne muscular dystrophy and spinal muscular atrophy and on the upcoming 2022 MDA Clinical & Scientific Conference.
BookmarkRelated Content
-
mySMAteam – FacebookmySMAteam is the social network for thos...
-
Will Parental Vaccine Hesitancy Retard the Embrace of Life-Saving Newborn Genetic Screening and Emerging Gene Therap...In these days of the never-ending pandem...
-
Loren A. Eng, MA, MBALoren Eng is the President of the Spinal...
-
Why Some Drugs Cost $2.1 Million per Dose and how one Company Plans to Change ThisWith a cost of $2.1 million for a one-do...
-
Anaesthetic Considerations in Posterior Instrumentation of Scoliosis Due to Spinal Muscular Atrophy: Case Series of ...Spinal muscular atrophy (SMA) is a rare ...
-
Risdiplam for the Use of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is one of ...
-
Expert Recommendations and Clinical Considerations in the Use of Onasemnogene Abeparvovec Gene Therapy for Spinal Mu...Spinal muscular atrophy (SMA) is an auto...
